NIKKEI 225
38,923.03 +435.13 (+1.13%) HANG SENG
18,403.04 +323.43 (+1.79%) CRUDE OIL
74.29 -2.70 (-3.51%) GOLD FUTURES
2,367.50 +21.70 (+0.93%) DOW
38,288.98 -397.34 (-1.03%) Bitcoin GBP
53,998.27 +767.45 (+1.44%)
LLY Jun 2024 360.000 call
| Previous close | 445.79 |
| Open | 445.79 |
| Bid | 471.45 |
| Ask | 474.50 |
| Strike | 360.00 |
| Expiry date | 2024-06-21 |
| Day's range | 445.79 - 445.79 |
| Contract range | N/A |
| Volume | |
| Open interest | 106 |
ZacksThe Zacks Analyst Blog Highlights Eli Lilly, T-Mobile US, BHP, American International and Exelon
Eli Lilly, T-Mobile US, BHP, American International and Exelon are part of the Zacks Analyst Blog.
Investor's Business DailyS&P 500 Giants Lead Five Healthy Stocks Near Buy Points
Eli Lilly, Novo Nordisk, Vertex Pharmaceuticals, Intuitive Surgical and Universal Health are all trading in or near buy zones. Medical stocks are often viewed as defensive growth stocks, because their growth is insulated from economic swings due to the government or insurance covering most of the costs. Eli Lilly is in a buy zone while weight-loss drug rival and fellow IBD Leaderboard member Novo Nordisk is setting up.
PR NewswireUpdated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting
Eli Lilly and Company (NYSE: LLY) today announced updated data from the Phase 1/2 clinical trial evaluating olomorasib as a monotherapy in patients with KRAS G12C-mutant advanced solid tumors and in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with KRAS G12C-mutant advanced non-small cell lung cancer (NSCLC). Olomorasib is an investigational, oral, potent, and highly selective second-generation inhibitor of the KRAS G12C protein. These data will be shared in o
